|
US6300361B1
(en)
*
|
1990-07-25 |
2001-10-09 |
Novartis Ag |
Stabilized pharmaceutical compositions comprising acid donors
|
|
DE4243279A1
(de)
*
|
1992-12-21 |
1994-06-23 |
Bayer Ag |
Substituierte Triole
|
|
US5399356A
(en)
*
|
1994-03-24 |
1995-03-21 |
The Procter & Gamble Company |
Process for making solid dose forms containing bismuth
|
|
JPH11512927A
(ja)
|
1995-08-17 |
1999-11-09 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
コレステロール合成を制御する遺伝子およびタンパク質
|
|
DE69625046T2
(de)
*
|
1995-12-22 |
2003-04-10 |
Kowa Co., Ltd. |
Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium
|
|
SK283348B6
(sk)
*
|
1996-04-05 |
2003-06-03 |
Takeda Chemical Industries, Ltd. |
Farmaceutický prípravok obsahujúci zlúčeninu s antagonickým účinkom na angiotenzín II
|
|
HUP9902165A3
(en)
|
1996-04-16 |
2001-01-29 |
Bayer Ag |
D-mannit and with big specific surface area process for preparing it and solid pharmaceuticals containing it
|
|
WO1997049681A1
(en)
*
|
1996-06-24 |
1997-12-31 |
Astra Aktiebolag (Publ) |
Polymorphic compounds
|
|
SE9603667D0
(sv)
*
|
1996-10-08 |
1996-10-08 |
Astra Ab |
Pharmaceutical compositions
|
|
SE9603668D0
(sv)
*
|
1996-10-08 |
1996-10-08 |
Astra Ab |
Pharmaceutical compositions
|
|
DE19725391A1
(de)
*
|
1997-06-16 |
1998-12-17 |
Bayer Ag |
Verfahren zur Herstellung von Arzneimittel, enthaltend HMG-CoA-Reduktase-Inhibitoren
|
|
US6465477B1
(en)
*
|
1997-08-18 |
2002-10-15 |
Kowa Company, Ltd. |
Stable pharmaceutical composition
|
|
US20060141036A1
(en)
*
|
1997-12-12 |
2006-06-29 |
Andrx Labs Llc |
HMG-CoA reductase inhibitor extended release formulation
|
|
US6235311B1
(en)
*
|
1998-03-18 |
2001-05-22 |
Bristol-Myers Squibb Company |
Pharmaceutical composition containing a combination of a statin and aspirin and method
|
|
US20010014352A1
(en)
|
1998-05-27 |
2001-08-16 |
Udit Batra |
Compressed tablet formulation
|
|
US5997905A
(en)
*
|
1998-09-04 |
1999-12-07 |
Mcneil-Ppc |
Preparation of pharmaceutically active particles
|
|
SI20070A
(sl)
|
1998-09-18 |
2000-04-30 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Nove soli inhibitorjev HMG-CoA reduktaze
|
|
US20020169145A1
(en)
*
|
1998-10-14 |
2002-11-14 |
Rajen Shah |
Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
|
|
US7939105B2
(en)
|
1998-11-20 |
2011-05-10 |
Jagotec Ag |
Process for preparing a rapidly dispersing solid drug dosage form
|
|
TWI230618B
(en)
*
|
1998-12-15 |
2005-04-11 |
Gilead Sciences Inc |
Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
|
|
SI20109A
(sl)
*
|
1998-12-16 |
2000-06-30 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Stabilna farmacevtska formulacija
|
|
AU2866400A
(en)
*
|
1999-03-08 |
2000-09-28 |
Merck & Co., Inc. |
Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
|
|
US6569461B1
(en)
|
1999-03-08 |
2003-05-27 |
Merck & Co., Inc. |
Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
|
|
EP1036563A1
(en)
*
|
1999-03-08 |
2000-09-20 |
MERCK & CO. INC. |
Delayed-release oral formulation of dihydroxy open acid simvastatin and salts and esters thereof
|
|
AU4988100A
(en)
*
|
1999-05-07 |
2000-11-21 |
Brigham And Women's Hospital |
Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
|
|
EP1225880A2
(en)
*
|
1999-11-04 |
2002-07-31 |
Andrx Corporation |
Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders
|
|
US20020107173A1
(en)
*
|
1999-11-04 |
2002-08-08 |
Lawrence Friedhoff |
Method of treating amyloid beta precursor disorders
|
|
GB0001621D0
(en)
*
|
2000-01-26 |
2000-03-15 |
Astrazeneca Ab |
Pharmaceutical compositions
|
|
WO2001056596A1
(en)
|
2000-02-04 |
2001-08-09 |
Children's Hospital Research Foundation |
Use of lysosomal acid lipase for treating atherosclerosis and related diseases
|
|
AU4688301A
(en)
*
|
2000-04-11 |
2001-10-23 |
Sankyo Co |
Stabilized pharmaceutical compositions containing calcium channel blockers
|
|
US6242003B1
(en)
|
2000-04-13 |
2001-06-05 |
Novartis Ag |
Organic compounds
|
|
GB0011163D0
(en)
*
|
2000-05-10 |
2000-06-28 |
Astrazeneca Ab |
Chemical compound
|
|
US6743926B2
(en)
*
|
2000-05-26 |
2004-06-01 |
Ciba Specialty Chemicals Corporation |
Process for the preparation of indole derivatives and intermediates of the process
|
|
US6806290B2
(en)
|
2000-06-09 |
2004-10-19 |
Lek Pharmaceuticals D.D. |
Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
|
|
ATE418979T2
(de)
|
2000-06-09 |
2009-01-15 |
Lek Pharmaceuticals |
Stabilisiertes arzneimittel und arzneizubereitung
|
|
JP2004501121A
(ja)
|
2000-06-09 |
2004-01-15 |
エルイーケー ファーマシューティカルズ ディー．ディー． |
安定した医薬効果を有する合成物、及びそれを含む医薬製剤
|
|
US8586094B2
(en)
|
2000-09-20 |
2013-11-19 |
Jagotec Ag |
Coated tablets
|
|
US7407484B2
(en)
|
2001-04-06 |
2008-08-05 |
Medic4All Inc. |
Physiological monitoring system for a computational device of a human subject
|
|
US20060127474A1
(en)
|
2001-04-11 |
2006-06-15 |
Oskar Kalb |
Pharmaceutical compositions comprising fluvastatin
|
|
GB0111077D0
(en)
|
2001-05-04 |
2001-06-27 |
Biochemie Gmbh |
Organic compounds
|
|
CA2445712A1
(en)
*
|
2001-05-31 |
2002-12-05 |
Cellegy Pharmaceuticals, Inc. |
Store operated calcium influx inhibitors and methods of use
|
|
JP2004536826A
(ja)
*
|
2001-06-21 |
2004-12-09 |
アンドルックス ファーマスーティカルズ インコーポレーテッド |
プラバスタチンを含む安定な薬剤組成物
|
|
EP2269609A3
(en)
|
2001-10-16 |
2012-07-11 |
Sloan-Kettering Institute for Cancer Research |
Treatment of neurodegenerative diseases and cancer of the brain with SAHA
|
|
US7183321B2
(en)
*
|
2001-12-17 |
2007-02-27 |
Bristol-Myers Squibb Company |
Antidiabetic formulation and method
|
|
EP1336405A1
(en)
*
|
2002-02-14 |
2003-08-20 |
Ranbaxy Laboratories, Ltd. |
Formulations of atorvastatin stabilized with alkali metal additions
|
|
US7148257B2
(en)
|
2002-03-04 |
2006-12-12 |
Merck Hdac Research, Llc |
Methods of treating mesothelioma with suberoylanilide hydroxamic acid
|
|
CA2632078C
(en)
|
2002-03-04 |
2012-08-14 |
Sloan-Kettering Institute For Cancer Research |
Methods of inducing terminal differentiation
|
|
US7456219B2
(en)
|
2002-03-04 |
2008-11-25 |
Merck Hdac Research, Llc |
Polymorphs of suberoylanilide hydroxamic acid
|
|
AU2003226051A1
(en)
*
|
2002-04-16 |
2003-11-03 |
Banyu Pharmaceutical Co., Ltd. |
Solid forms of salts with tyrosine kinase activity
|
|
DK2336359T3
(en)
|
2002-05-09 |
2016-05-30 |
Brigham & Womens Hospital |
1L1RL-1 as cardiovascular disease marker
|
|
CA2385529A1
(en)
*
|
2002-05-21 |
2003-11-21 |
Bernard Charles Sherman |
Stable dosage forms comprising atorvastatin calcium
|
|
SI1515717T1
(sl)
*
|
2002-06-13 |
2009-02-28 |
Novartis Ag |
Kalcijeve soli statinov, izvedenih iz indola
|
|
US20040006109A1
(en)
*
|
2002-07-03 |
2004-01-08 |
Rajneesh Taneja |
Liquid dosage forms of non-enterically coated acid-labile drugs
|
|
US20080293750A1
(en)
*
|
2002-10-17 |
2008-11-27 |
Anna Helgadottir |
Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
|
|
US20060019269A1
(en)
*
|
2002-10-17 |
2006-01-26 |
Decode Genetics, Inc. |
Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
|
|
US20040198800A1
(en)
*
|
2002-12-19 |
2004-10-07 |
Geoffrey Allan |
Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
|
|
JP2006521287A
(ja)
|
2002-12-20 |
2006-09-21 |
エスティ．ジェイムス アソシエイト エルエルシー／フェイバー リサーチ シリーズ |
医薬製剤用の高圧圧縮
|
|
CA2508840A1
(en)
|
2002-12-20 |
2004-07-08 |
Pfizer Products Inc. |
Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
|
|
US20040132771A1
(en)
*
|
2002-12-20 |
2004-07-08 |
Pfizer Inc |
Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
|
|
CA2519458A1
(en)
*
|
2003-03-17 |
2004-09-30 |
Japan Tobacco Inc. |
Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
|
|
TWI393560B
(zh)
*
|
2003-05-02 |
2013-04-21 |
Japan Tobacco Inc |
包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
|
|
US7166638B2
(en)
*
|
2003-05-27 |
2007-01-23 |
Nicox S.A. |
Statin derivatives
|
|
JP4901474B2
(ja)
|
2003-05-30 |
2012-03-21 |
ランバクシー ラボラトリーズ リミテッド |
置換ピロール誘導体
|
|
PT1638937E
(pt)
*
|
2003-06-18 |
2009-01-27 |
Teva Pharma |
Forma xiv cristalina de fluvastatina sódica, processos para a sua preparação, composições que a contêm e métodos de utilização
|
|
JP2007077174A
(ja)
*
|
2003-06-25 |
2007-03-29 |
Novartis Ag |
フルバスタチン含有錠剤
|
|
DE602004027808D1
(de)
*
|
2003-06-25 |
2010-08-05 |
Novartis Ag |
Tablette enthaltend fluvastatin und calciumcarmellose
|
|
GB2404336A
(en)
*
|
2003-07-30 |
2005-02-02 |
Cipla Ltd |
Stabilisation of therapeutic agents using a carbonate salt of an amino acid, preferably in the presence of a saccharide, & pharmaceutical compositions thereof
|
|
US7312353B2
(en)
|
2003-08-21 |
2007-12-25 |
Merck Frost Canada & Co. |
Cathespin cysteine protease inhibitors
|
|
EP1510208A1
(en)
|
2003-08-22 |
2005-03-02 |
Fournier Laboratories Ireland Limited |
Pharmaceutical composition comprising a combination of metformin and statin
|
|
WO2005051298A2
(en)
|
2003-11-19 |
2005-06-09 |
Metabasis Therapeutics, Inc. |
Novel phosphorus-containing thyromimetics
|
|
WO2005053683A1
(en)
*
|
2003-11-26 |
2005-06-16 |
Duke University |
A method of preventing or treating glaucoma
|
|
WO2005063294A1
(ja)
|
2003-12-30 |
2005-07-14 |
Kowa Company, Ltd. |
γ-セクレターゼ複合体形成阻害剤
|
|
US8163797B2
(en)
*
|
2003-12-31 |
2012-04-24 |
Actavis Elizabeth Llc |
Method of treating with stable pravastatin formulation
|
|
US8158362B2
(en)
*
|
2005-03-30 |
2012-04-17 |
Decode Genetics Ehf. |
Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
|
|
US20100216863A1
(en)
*
|
2004-01-30 |
2010-08-26 |
Decode Genetics Ehf. |
Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
|
|
US7803838B2
(en)
*
|
2004-06-04 |
2010-09-28 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
|
AU2005271407A1
(en)
*
|
2004-08-06 |
2006-02-16 |
Transform Pharmaceuticals, Inc. |
Novel fenofibrate formulations and related methods of treatment
|
|
US20090042979A1
(en)
*
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
|
JP2008509154A
(ja)
*
|
2004-08-06 |
2008-03-27 |
トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド |
新規なスタチン薬剤組成物および関連治療方法
|
|
DE102004042139B4
(de)
*
|
2004-08-31 |
2009-06-10 |
Aristocon Verwaltungs- Gmbh |
Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
|
|
ES2439229T3
(es)
|
2004-10-06 |
2014-01-22 |
The Brigham And Women's Hospital, Inc. |
Relevancia de niveles logrados de marcadores de inflamación sistémica tras el tratamiento
|
|
ES2255426B1
(es)
*
|
2004-10-19 |
2007-08-16 |
Gp Pharm, S.A. |
Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
|
|
AU2005314230B2
(en)
|
2004-12-09 |
2011-05-19 |
Merck Sharp & Dohme Corp. |
Estrogen receptor modulators
|
|
US20070129402A1
(en)
*
|
2004-12-27 |
2007-06-07 |
Eisai Research Institute |
Sustained release formulations
|
|
US8481565B2
(en)
|
2004-12-27 |
2013-07-09 |
Eisai R&D Management Co., Ltd. |
Method for stabilizing anti-dementia drug
|
|
NZ560386A
(en)
*
|
2005-01-31 |
2009-12-24 |
Mylan Lab Inc |
Pharmaceutical composition comprising hydroxylated nebivolol
|
|
JP2008531691A
(ja)
|
2005-03-02 |
2008-08-14 |
メルク エンド カムパニー インコーポレーテッド |
カテプシンｋ阻害組成物
|
|
US20060229277A1
(en)
*
|
2005-04-08 |
2006-10-12 |
Orbus Pharma, Inc. |
Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
|
|
NZ562120A
(en)
*
|
2005-04-28 |
2010-07-30 |
Eisai R&D Man Co Ltd |
Composition comprising donepezil and memantine as antidementia agents
|
|
WO2006123182A2
(en)
|
2005-05-17 |
2006-11-23 |
Merck Sharp & Dohme Limited |
Cyclohexyl sulphones for treatment of cancer
|
|
AP2896A
(en)
|
2005-05-31 |
2014-05-31 |
Mylan Lab Inc |
Compositions comprising nebivolol
|
|
JP5490409B2
(ja)
|
2005-07-11 |
2014-05-14 |
コルトリア・コーポレーション |
スタチンおよびメチルニコチンアミド誘導体を含んでなるリポ蛋白質異常の処置用調剤
|
|
WO2007016757A1
(en)
*
|
2005-08-05 |
2007-02-15 |
Orbus Pharma Inc. |
Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor
|
|
PE20070427A1
(es)
*
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
|
|
US8119358B2
(en)
|
2005-10-11 |
2012-02-21 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
|
KR101329112B1
(ko)
|
2005-11-08 |
2013-11-14 |
랜박시 래보러터리스 리미티드 |
(3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
|
|
US20090247603A1
(en)
*
|
2005-12-23 |
2009-10-01 |
Orbus Pharma, Inc. |
Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
|
|
US20070202159A1
(en)
*
|
2006-02-02 |
2007-08-30 |
Mathur Rajeev S |
Pharmaceutical composition comprising stabilized statin particles
|
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
CN101426478A
(zh)
*
|
2006-02-24 |
2009-05-06 |
特瓦制药工业有限公司 |
氟伐他汀钠药物组合物
|
|
US20070238716A1
(en)
*
|
2006-03-14 |
2007-10-11 |
Murthy Ayanampudi S R |
Statin stabilizing dosage formulations
|
|
US7553854B2
(en)
|
2006-04-19 |
2009-06-30 |
Novartis Vaccines And Diagnostics, Inc. |
6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
|
|
WO2007146229A2
(en)
|
2006-06-07 |
2007-12-21 |
Tethys Bioscience, Inc. |
Markers associated with arteriovascular events and methods of use thereof
|
|
EP2037928B1
(en)
|
2006-06-26 |
2012-01-11 |
Amgen Inc. |
Methods for treating atherosclerosis
|
|
CN101511348B
(zh)
*
|
2006-08-30 |
2012-04-18 |
国立大学法人九州大学 |
含有包封他汀类之纳米颗粒的药物组合物
|
|
AU2007300627B2
(en)
|
2006-09-22 |
2012-02-16 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
|
MX2009002993A
(es)
*
|
2006-09-26 |
2009-04-01 |
Novartis Ag |
Composiciones farmaceuticas que comprenden un modulador de s1p.
|
|
EP1923053A1
(en)
*
|
2006-09-27 |
2008-05-21 |
Novartis AG |
Pharmaceutical compositions comprising nilotinib or its salt
|
|
EP1911441A3
(en)
*
|
2006-10-11 |
2008-08-06 |
Lupin Limited |
Controlled release color stable pharmaceutical dosage form of HMG-COA reductase inhibitors, free of alkalizing or buffering agents
|
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
|
WO2008064259A2
(en)
*
|
2006-11-21 |
2008-05-29 |
Biokey, Inc. |
Solid dispersion composition comprising fluvastatin
|
|
US20110052688A1
(en)
*
|
2006-11-21 |
2011-03-03 |
San-Laung Chow |
Solid dispersion composition
|
|
AU2008204380B2
(en)
|
2007-01-10 |
2013-08-15 |
Msd Italia S.R.L. |
Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
|
|
MX2009009304A
(es)
|
2007-03-01 |
2009-11-18 |
Novartis Ag |
Inhibidores de cinasa pim y metodos para su uso.
|
|
WO2008124121A1
(en)
*
|
2007-04-06 |
2008-10-16 |
Scidose, Llc |
Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
|
|
WO2008124120A1
(en)
*
|
2007-04-09 |
2008-10-16 |
Scidose, Llc |
Combinations of statins and anti-obesity agent
|
|
US20080249156A1
(en)
*
|
2007-04-09 |
2008-10-09 |
Palepu Nageswara R |
Combinations of statins and anti-obesity agent and glitazones
|
|
CN102317786A
(zh)
|
2007-04-18 |
2012-01-11 |
特提斯生物科学公司 |
糖尿病相关性生物学标记物及其使用方法
|
|
US8293769B2
(en)
|
2007-05-21 |
2012-10-23 |
Novartis Ag |
CSF-1R inhibitors, compositions, and methods of use
|
|
EP2170076B1
(en)
|
2007-06-27 |
2016-05-18 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
|
EP2489731B1
(en)
|
2007-07-26 |
2014-08-27 |
Amgen, Inc |
Modified lecithin-cholesterol acyltransferase enzymes
|
|
CA2709677C
(en)
|
2007-12-21 |
2017-03-14 |
Lin Zhi |
Selective androgen receptor modulators (sarms) and uses thereof
|
|
EP2309992B1
(en)
*
|
2008-06-27 |
2017-10-25 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Pharmaceutical composition comprising a statin
|
|
TR201101807T2
(tr)
*
|
2008-06-27 |
2012-02-21 |
Abd� �Brah�M �La� Sanay� Ve T�Caret Anon�M ��Rket�@ |
Rosuvastatin kalsiyumun farmasotik bileşimleri
|
|
EP2138165A1
(en)
|
2008-06-27 |
2009-12-30 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Pharmaceutical composition comprising a statin
|
|
WO2010093601A1
(en)
|
2009-02-10 |
2010-08-19 |
Metabasis Therapeutics, Inc. |
Novel sulfonic acid-containing thyromimetics, and methods for their use
|
|
JP2012096998A
(ja)
*
|
2009-02-27 |
2012-05-24 |
Kowa Co |
安定なカプセル製剤及びその製造方法
|
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
|
TR200904341A2
(tr)
|
2009-06-03 |
2010-12-21 |
Bi̇lgi̇ç Mahmut |
Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
|
|
MX2012004377A
(es)
|
2009-10-14 |
2012-06-01 |
Merck Sharp & Dohme |
Piperidinas sustituidas que aumentan la actividad de p53 y sus usos.
|
|
WO2011087629A2
(en)
*
|
2009-12-22 |
2011-07-21 |
Fmc Corporation |
Microcrystalline cellulose and calcium carbonate compositions useful as recompactible pharmaceutical excipients
|
|
EP2531163A1
(en)
|
2010-02-01 |
2012-12-12 |
The Hospital For Sick Children |
Remote ischemic conditioning for treatment and preventon of restenosis
|
|
KR20130040851A
(ko)
|
2010-03-31 |
2013-04-24 |
더 호스피탈 포 식 칠드런 |
심근 경색 후 결과를 개선시키기 위한 원격 허혈 처치의 사용
|
|
RU2012147442A
(ru)
|
2010-04-08 |
2014-05-20 |
Дзе Хоспитал Фор Сик Чилдрен |
Применение дистантного ишемического кондиционирования при травматическом повреждении
|
|
US8372877B2
(en)
|
2010-04-16 |
2013-02-12 |
Cumberland Pharmaceuticals |
Stabilized statin formulations
|
|
TR201009397A2
(tr)
|
2010-11-11 |
2012-05-21 |
Bi̇lgi̇ç Mahmut |
Rosuvastatin içeren farmasötik bileşimler.
|
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
|
JP5829607B2
(ja)
*
|
2010-06-30 |
2015-12-09 |
持田製薬株式会社 |
ω３脂肪酸の配合製剤
|
|
EP3330377A1
(en)
|
2010-08-02 |
2018-06-06 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
|
MX354686B
(es)
*
|
2010-08-04 |
2018-03-15 |
Gruenenthal Gmbh Star |
Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil-)-4-fenil-4'.9'-dihidro-3'h-espi ro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento de dolor neuropatico.
|
|
EP2606134B1
(en)
|
2010-08-17 |
2019-04-10 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
|
US20130156720A1
(en)
|
2010-08-27 |
2013-06-20 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
|
EP2615916B1
(en)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel erk inhibitors
|
|
EP2626069A4
(en)
|
2010-10-06 |
2014-03-19 |
Univ Tokyo |
A MEDICINAL PRODUCT FOR THE PREVENTION AND TREATMENT OF A DERY LYMPH
|
|
ES2663009T3
(es)
|
2010-10-29 |
2018-04-10 |
Sirna Therapeutics, Inc. |
Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
|
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
|
US8791162B2
(en)
|
2011-02-14 |
2014-07-29 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
|
JP5988963B2
(ja)
*
|
2011-04-12 |
2016-09-07 |
沢井製薬株式会社 |
ピタバスタチン含有製剤及びその製造方法
|
|
CN103732592A
(zh)
|
2011-04-21 |
2014-04-16 |
默沙东公司 |
胰岛素样生长因子-1受体抑制剂
|
|
WO2012153181A1
(en)
*
|
2011-05-11 |
2012-11-15 |
Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi |
Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts
|
|
KR101830977B1
(ko)
*
|
2011-06-30 |
2018-02-21 |
한미약품 주식회사 |
오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
|
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
|
JP6635655B2
(ja)
|
2011-12-08 |
2020-01-29 |
アムジエン・インコーポレーテツド |
ヒトｌｃａｔ抗原結合タンパク質および治療法におけるそれらの使用
|
|
EP3919620A1
(en)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
|
WO2014022195A1
(en)
|
2012-08-01 |
2014-02-06 |
Tavakoli Zahra |
Free flowing, frozen compositions comprising a therapeutic agent
|
|
EP3124017A1
(en)
|
2012-08-08 |
2017-02-01 |
Kowa Company, Ltd. |
Pharmaceutical composition comprising pitavastatine
|
|
RU2660429C2
(ru)
|
2012-09-28 |
2018-07-06 |
Мерк Шарп И Доум Корп. |
Новые соединения, которые являются ингибиторами erk
|
|
JP6290237B2
(ja)
|
2012-11-28 |
2018-03-07 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
癌を処置するための組成物および方法
|
|
AR094116A1
(es)
|
2012-12-20 |
2015-07-08 |
Merck Sharp & Dohme |
Imidazopiridinas sustituidas como inhibidores de hdm2
|
|
EP2951180B1
(en)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
|
AU2014235854B2
(en)
|
2013-03-21 |
2019-04-11 |
Eupraxia Pharmaceuticals USA LLC |
Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
|
|
CN104069502B
(zh)
*
|
2013-03-29 |
2018-02-16 |
北京罗诺强施医药技术研发中心有限公司 |
复合骨架材料及其药物组合物
|
|
RO129060B1
(ro)
|
2013-04-25 |
2014-11-28 |
Antibiotice S.A. |
Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
|
|
KR101597004B1
(ko)
|
2013-07-25 |
2016-02-23 |
씨제이헬스케어 주식회사 |
서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
CA2923272A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
|
WO2015051479A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
|
GB201319791D0
(en)
|
2013-11-08 |
2013-12-25 |
Sigmoid Pharma Ltd |
Formulations
|
|
EP3613418A1
(en)
|
2014-01-17 |
2020-02-26 |
Ligand Pharmaceuticals, Inc. |
Methods and compositions for modulating hormone levels
|
|
WO2015120580A1
(en)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
|
WO2015185240A1
(en)
|
2014-06-04 |
2015-12-10 |
Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. |
Compositions containing simvastatin in omega-3 polyunsaturated fatty acids
|
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
|
BR112017009521A2
(pt)
|
2014-11-11 |
2017-12-19 |
Shionogi & Co |
comprimido de múltiplas camadas que contém um fármaco instável à luz
|
|
ES2672993T3
(es)
|
2015-10-27 |
2018-06-19 |
Eupraxia Pharmaceuticals Inc. |
Formulaciones de liberación sostenida de anestésicos locales
|
|
WO2018071283A1
(en)
|
2016-10-12 |
2018-04-19 |
Merck Sharp & Dohme Corp. |
Kdm5 inhibitors
|
|
RU2648445C1
(ru)
*
|
2016-11-03 |
2018-03-26 |
Светлана Асылхановна Астафьева |
6-(3,3- диметил-3,4-дигидроизохинолин-1-ил) аминогексановая кислота и фармацевтическая композиция на ёе основе, обладающие анальгетической активностью
|
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
KR101954568B1
(ko)
*
|
2018-01-22 |
2019-03-05 |
한미약품 주식회사 |
오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
|
|
US11981701B2
(en)
|
2018-08-07 |
2024-05-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
US11993602B2
(en)
|
2018-08-07 |
2024-05-28 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
EP4077282A4
(en)
|
2019-12-17 |
2023-11-08 |
Merck Sharp & Dohme LLC |
PRMT5 INHIBITORS
|
|
WO2024180169A1
(en)
|
2023-03-02 |
2024-09-06 |
Carcimun Biotech Gmbh |
Means and methods for diagnosing cancer and/or an acute inflammatory disease
|